Urinary Glycosaminoglycans: Characterization and Quantification.
1,9-Dimethylmethylene blue
Glycosaminoglycans
Thin layer chromatography
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
25
1
2023
Statut:
ppublish
Résumé
The growing body of evidence supports the potential of using urinary glycosaminoglycans (uGAGs) levels as biomarkers to guide diagnosis and as predictive biomarkers of treatment efficacy. Recently, studies have shown that, in addition to MPS, the prognosis and treatment of cancers and viral infections, including COVID-19, are enabled by characterization and/or traits by GAGs. Reliable and accessible detection and assay protocols of urinary GAGs are therefore of great support for laboratory workers and clinicians. Here we describe a semiquantitative and quantitative urinary glycosaminoglycans determination using 1,9-dimethylmethylene blue (DMB) and the characterization of uGAGs using thin layer chromatography (TLC).
Identifiants
pubmed: 36662462
doi: 10.1007/978-1-0716-2946-8_5
doi:
Substances chimiques
Glycosaminoglycans
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-69Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Fdil N, Sabir E-S, Ezoubeiri A et al (2020) Implementation of an affordable method for MPS diagnosis from urine screening to enzymatic confirmation: results of a pilot study in Morocco. Clin Lab 66. https://doi.org/10.7754/Clin.Lab.2019.190720
Sabir E, Lafhal K, Ezoubeiri A et al (2020) Usefulness of urinary glycosaminoglycans assay for a mucopolysaccharidosis-specific screening. Pediatr Int 62:1077–1085
doi: 10.1111/ped.14278
Shimada T, Tomatsu S, Mason RW, et al (2014) Di-sulfated keratan sulfate as a novel biomarker for mucopolysaccharidosis II, IVA, and IVB. In: JIMD reports, vol 21. Springer, pp 1–13
Kakkis E, Marsden D (2020) Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses. Mol Genet Metab 130:7–15
doi: 10.1016/j.ymgme.2020.02.006
Gandhi NS, Mancera RL (2008) The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 72:455–482
doi: 10.1111/j.1747-0285.2008.00741.x
Wei J, Hu M, Huang K et al (2020) Roles of proteoglycans and glycosaminoglycans in cancer development and progression. Int J Mol Sci 21:5983
doi: 10.3390/ijms21175983
Hillemeyer L, Espinoza-Sanchez NA, Greve B et al (2022) The cell surface heparan sulfate proteoglycan syndecan-3 promotes ovarian cancer pathogenesis. Int J Mol Sci 23:5793
doi: 10.3390/ijms23105793
Wadowski PP, Jilma B, Kopp CW et al (2021) Glycocalyx as possible limiting factor in COVID-19. Front Immunol 12:607306
doi: 10.3389/fimmu.2021.607306
Bauer S, Zhang F, Linhardt RJ (2021) Implications of glycosaminoglycans on viral zoonotic diseases. Diseases 9:85
doi: 10.3390/diseases9040085
Queisser KA, Mellema RA, Middleton EA et al (2021) COVID-19 generates hyaluronan fragments that directly induce endothelial barrier dysfunction. JCI Insight 6:17
doi: 10.1172/jci.insight.147472